Sponsored Content by ACROBiosystemsReviewed by Aimee MolineuxAug 5 2024 Since the successful production of humanized antibodies in the 1980s, antibody-based medications have become increasingly essential in clinical treatment, taking advantage of their low immunogenicity and long-term dosing.
Representative drugs, including etanercept, alefacept, and abatacept, have given patients more effective treatment alternatives. The tremendous developments in antibody technology have transformed the biopharmaceutical landscape, providing new hope for patients suffering from a variety of ailments. Key to antibody drug development: Half-life optimization The half-life of Fc fusion proteins and antibody medicines is an important factor during the development process. The serum half-life of IgG1 in healthy persons is around 21 days, which is linked to the interaction between IgG and the neonatal Fc receptor .
The Fluorescence Resonance Energy Transfer theory was first postulated in 1948 and experimentally proven in 1967. This approach can detect molecular interactions within a range of 1.0-6.0 nm.